CEVA, Inc. Schedules Fourth Quarter and Year End 2014 Earnings Release and Conference Call

MOUNTAIN VIEW, Calif., Jan. 8, 2015 /TRENDINGGLOBALNEWS/ -- CEVA, Inc. (NASDAQ: CEVA), the leading licensor of DSP and IP platforms for vision, audio, communications and connectivity, will announce results for the fourth quarter and full year ended December 31, 2014 on February 3rd, 2015 before the NASDAQ market opens.

Following the release, CEVA management will conduct a conference call at 8:30 a.m. Eastern Time to discuss the operating performance for the quarter.

The conference call will be available via the following dial in numbers:

• U.S. Participants: Dial 1-866-364-3869 (Access Code: CEVA)
• International Participants: Dial +1-412-902-4215 (Access Code: CEVA)

The conference call will also be available live via the Internet at the following link:  http://www.videonewswire.com/event.asp?id=101303.  Please go to the web site at least fifteen minutes prior to the call to register, download and install any necessary audio software.

For those who cannot access the live broadcast, a replay will be available by dialing +1-877-344-7529 or +1-412-317-0088 (access code: 10058291) from one hour after the end of the call until 9:00 a.m. (Eastern Time) on February 17, 2015. The replay will also be available at CEVA's web site www.ceva-dsp.com.

About CEVA, Inc.
CEVA is the world's leading licensor of DSP-based IP platforms for vision, audio, and communications, and connectivity IPs for Wi-Fi® and Bluetooth®. CEVA's portfolio includes comprehensive technologies for computer vision and computational photography, advanced audio and voice processing, 2G/3G/4G/LTE/LTE-A baseband processing, connectivity (including 802.11ac and Bluetooth Low Energy) and serial storage (SATA & SAS). In 2013, CEVA's IP was shipped in more than one billion devices, including 40% of handsets shipped worldwide, powering smartphones from many of the world's leading OEMs such as Coolpad, HTC, Huawei, Lenovo, LG, Nokia, Samsung, TCL, Xiaomi and ZTE. For more information, visit www.ceva-dsp.com. Follow CEVA on twitter at www.twitter.com/cevadsp.

source:http://www.prnewswire.com/

Biotechnology Stocks Trader's Buzzers : Achillion Pharmaceuticals, (ACHN), Advaxis, Inc. (ADXS) , Alexion Pharmaceuticals, (ALXN) , Amgen, (AMGN) , Albany Molecular Research, (AMRI)

Biotechnology is the use of biological processes, organisms, or systems to manufacture products intended to improve the quality of human life. The earliest biotechnologists were farmers who developed improved species of plants and animals by cross pollenization or cross breeding. In recent years, biotechnology has expanded in sophistication, scope, and applicability.

The science of biotechnology can be broken down into subdisciplines called red, white, green, and blue. Red biotechnology involves medical processes such as getting organisms to produce new drugs, or using stem cells to regenerate damaged human tissues and perhaps re-grow entire organs. White (also called gray) biotechnology involves industrial processes such as the production of new chemicals or the development of new fuels for vehicles. Green biotechnology applies to agriculture and involves such processes as the development of pest-resistant grains or the accelerated evolution of disease-resistant animals. Blue biotechnology, rarely mentioned, encompasses processes in marine and aquatic environments, such as controlling the proliferation of noxious water-borne organisms. {1}

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed declined -0.33% to $12.25,recently declared positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422.

"We believe that achievement of 100 percent SVR4 in six weeks in the ACH-3102 proxy study, combined with the high potency and safety demonstrated by ACH-3422, highlights the ability of our exceptional, fully owned portfolio to excel in the HCV market," commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "We look forward to initiating in 2015 short duration, pan-genotypic Phase 2 therapeutic trials to evaluate the doublet of ACH-3102 and ACH-3422, with the ultimate goal of improving patient care and access to treatment."

Advaxis, Inc. (NASDAQ:ADXS) closed lower -8.87% to $8.01, a biotechnology organization developing cancer immunotherapies, declared that its Lm-LLO immunotherapy technology was highlighted on FOX News Channel's Sunday Housecall. The segment, which aired on December 28, 2014, featured Drs. Marc Siegel and David Samadi discussing Advaxis's cancer immunotherapy as a potential treatment for a range of cancer indications, including breast, prostate, osteosarcoma, and head and neck, due to its potential to trigger the immune system to directly attack cancer cells.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) closed gained 0.05% to $185.03, recently declared completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for the treatment of hypophosphatasia (HPP). HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.1-5

Amgen, Inc. (NASDAQ:AMGN) closed declined -0.83% to $159.29, Amgen, Inc. and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, recently declared a contract in which Amgen has become a LabCentral platinum sponsor. As part of the sponsorship contract, Amgen can nominate up to two promising life-sciences and biotech startup companies per year to take up residence in LabCentral's Kendall Square facilities.

Albany Molecular Research, Inc. (NASDAQ:AMRI) closed increased 2.58% to $16.28, Levi & Korsinsky declares that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Albany Molecular Research Inc. (“Albany Molecular” or the “Company”) (AMRI) securities between August 5, 2014 and November 5, 2014.

 TAGs:

Achillion Pharmaceuticals, NASDAQ:ACHN, Advaxis, NASDAQ:ADXS , Alexion Pharmaceuticals, NASDAQ:ALXN , Amgen, NASDAQ:AMGN , Albany Molecular Research, NASDAQ:AMRI, ACHN, ADXS, ALXN, AMGN,AMRI

Source {1}: techtarget.com

Dot Hill to Attend The Benchmark Company's Micro Cap Discovery Conference

Dot Hill Systems Corp. (Nasdaq:HILL), a trusted supplier of innovative enterprise class storage systems, declared that Dana Kammersgard, the organization's president and chief executive officer, and Hanif Jamal, the organization's chief financial officer, will attend The Benchmark Company, LLC's Micro Cap Discovery Conference on Thursday, December 11, 2014. The one-on-one conference will be held at The Palmer House Hilton in Chicago, IL from 8:00 a.m. to 2:30 p.m. Please contact your Benchmark representative to schedule a meeting.

About Dot Hill

Leveraging its proprietary Assured family of storage solutions, Dot Hill solves many of today's most challenging storage problems – helping IT to improve performance, raise accessibility, simplify operations, and reduce costs. Dot Hill's solutions combine breakthrough software with the industry's most flexible and extensive hardware platform and automated administration to deliver best-in-class solutions. Headquartered in Longmont, Colorado, Dot Hill has offices and/or representatives in China, Germany, India, Japan, Singapore, the United Kingdom, and the United States. For more information, visit www.dothill.com.